Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

PHASE3CompletedINTERVENTIONAL
Enrollment

543

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2008

Conditions
DyslipidemiasCoronary Heart DiseaseCombined (Atherogenic) DyslipidemiaMixed Dyslipidemia
Interventions
DRUG

ABT-335

135 mg capsule, daily, 12 weeks

DRUG

placebo

placebo capsule, daily, 12 weeks

DRUG

atorvastatin

40 mg, tablet, daily, 12 weeks

DRUG

ezetimibe

10 mg capsule, daily, 12 weeks

Trial Locations (118)

13790

Johnson City

15216

Pittsburgh

16635

Duncansville

16684

Tipton

17740

Jersey Shore

18940

Newtown

18944

Perkasie

18960

Sellersville

18974

Warminster

19027

Melrose Park

19114

Philadelphia

19152

Philadelphia

19438

Harleysville

19446

Lansdale

20745

Oxon Hill

21209

Baltimore

23294

Richmond

23455

Virginia Beach

23502

Norfolk

24014

Roanoke

25677

Statesville

27103

Winston-Salem

27609

Raleigh

28144

Salisbury

28209

Charlotte

28557

Morehead City

28601

Hickory

29485

Summerville

29615

Greenville

29621

Anderson

29651

Greer

29681

Simpsonville

30024

Suwanee

30076

Roswell

30189

Woodstock

30342

Atlanta

30904

Augusta

32117

Holly Hill

32168

New Smyrna Beach

32174

Ormond Beach

32216

Jacksonville

32259

Jacksonville

32750

Longwood

33002

Pembroke Pines

33173

Miami

33484

Delray Beach

33607

Tampa

33756

Clearwater

33880

Winter Haven

33907

Fort Myers

34233

Sarasota

34471

Ocala

34652

New Port Richey

34741

Kissimmee

35023

Hueytown

35051

Columbiana

35209

Birmingham

35406

Tuscaloosa

36360

Ozark

37205

Nashville

38654

Olive Branch

40213

Louisville

40353

Mount Sterling

44260

Mogadore

44483

Warren

45040

Mason

45219

Cincinnati

46260

Indianapolis

47713

Evansville

47714

Evansville

52242

Iowa City

53719

Madison

55435

Edina

59101

Billings

60607

Chicago

60610

Chicago

61602

Peoria

63110

St Louis

63141

St Louis

63376

City of Saint Peters

66202

Overland Park

67005

Arkansas City

67207

Wichita

70458

Slidell

71913

Hot Springs

74136

Tulsa

75230

Dallas

76104

Fort Worth

77030

Houston

78229

San Antonio

80206

Denver

80904

Colorado Springs

83704

Boise

84088

West Jordan

84102

Salt Lake City

84103

Salt Lake City

84107

Salt Lake City

85635

Sierra Vista

89123

Las Vegas

90057

Los Angeles

90650

Norwalk

90806

Long Beach

90822

Long Beach

91307

West Hills

92701

Santa Ana

92780

Tustin

94520

Concord

95608

Carmichael

95661

Roseville

95825

Sacramento

97123

Hillsboro

99216

Spokane

02301

Brockton

08009

Berlin

07202

Elizabeth

08844

Hillsborough

08611

Trenton

02864

Cumberland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00639158 - Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood | Biotech Hunter | Biotech Hunter